July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Systemic Pentosan Polysulfate Administration Causes Retinal Function Loss in the C57Bl/6J Mouse
Author Affiliations & Notes
  • Preston Girardot
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
    Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Georgia, United States
  • Xian Zhang
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
    Department of Ophthalmology, Second Xiangya Hospital, Central South University, Changsha, China
  • Isabelle Gefke
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Wenfei Wu
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Adam Marcus Hanif
    Emory University School of Medicine, Atlanta, Georgia, United States
  • Nieraj Jain
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
  • John M Nickerson
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
  • Jeffrey H Boatright
    Department of Ophthalmology, Emory University, Atlanta, Georgia, United States
    Center for Visual and Neurocognitive Rehabilitation, Atlanta VA Medical Center, Georgia, United States
  • Footnotes
    Commercial Relationships   Preston Girardot, None; Xian Zhang, None; Isabelle Gefke, None; Wenfei Wu, None; Adam Hanif, None; Nieraj Jain, None; John Nickerson, None; Jeffrey Boatright, None
  • Footnotes
    Support  Abraham J and Phyllis Katz Foundation, NIH R01EY028450, NIH R01EY028859, NIH R01EY03057, NIH R01EY021592, Foundation Fighting Blindness, VA I01RX002806, VA I21RX001924, VA RR&D C9246C, NIH P30EY06360, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2352. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Preston Girardot, Xian Zhang, Isabelle Gefke, Wenfei Wu, Adam Marcus Hanif, Nieraj Jain, John M Nickerson, Jeffrey H Boatright; Systemic Pentosan Polysulfate Administration Causes Retinal Function Loss in the C57Bl/6J Mouse. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2352. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pentosan Polysulfate Sodium (PPS) is a United States Food and Drug Administration-approved drug for the management of bladder pain or discomfort associated with interstitial cystitis. We recently reported a novel maculopathy suggestive of a primary retinal pigment epithelium (RPE) injury in patients with a history of chronic PPS use [Pearce, Chen, Jain 2018]. In an initial prospective test of effects of systemic PPS administration on visual outcomes, we injected mice intraperitoneally with PPS and measured their ocular function and morphology for several weeks.

Methods : Five male C57Bl/6J mice were given intraperitoneal injections of phosphate buffered saline (PBS) or PPS in PBS or (2 vehicle, 3 drug). Injections were given daily, 6 days a week for 28 days. Concentration of drug was 25 mg/kg mouse weight. Once a week mice underwent non-invasive assays: retinal function was assessed by electroretinography (ERG), retinal morphology was assessed by spectral domain-optical coherence tomography (SD-OCT), and retinal angiography was assessed by confocal scanning laser ophthalmoscopy (cSLO).

Results : Over 17 days in which we gave 15 injections, we saw a main drug effect on ERG a- and b-wave amplitudes (p=0.0362 and 0.0458, respectively, two-way repeated measures ANOVA). At the end of this period, mean ERG a-wave amplitude was 20% lower in the drug-treated animals, and B-wave amplitude was 10% lower. Differences in in-vivo imaging were less pronounced, but, beginning in the third week of the study, one mouse receiving PPS did develop abnormal spots of discoloration on the fundus of one eye.

Conclusions : Systemic administration of PPS causes retinal deficits. The current pilot study tested high doses over a relatively short duration, while our ongoing studies are testing chronic administration effects. We expect that this model will be useful for testing mechanistic hypotheses and could lead to unexpected discoveries in retinal biology.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×